Bechtel Medical, Inc. appears in FDA 510(k) records as the applicant for K262232, a Traditional premarket notification received on June 30, 2026 and decided substantially equivalent on November 6, 2026. The filing covers the Wound VOX NPWT System (V1-01-01) together with a 300ml collection canister and supply tubing, a Y-connector, three dressing kit sizes, an adhesive drape, a foam dressing, a suction bell assembly and two wound contact layer sizes. The applicant address on the record is in Phoenixville, Pennsylvania; that filing address is not treated here as a verified headquarters. [1][2][5]
What the clearance covers
The K262232 record lists eleven named items under a single submission: the Wound VOX NPWT System (V1-01-01), the Wound VOX 300ml Collection Canister & Supply Tubing (CC-00-03), the Wound VOX Y-Connector (YK-01-13), Wound VOX Dressing Kits in small, medium and large (DK-01-01 through DK-01-03), the Wound VOX Adhesive Drape (DK-01-04), Wound VOX Foam Dressing (DK-01-05), Wound VOX Suction Bell Assembly (DK-01-06) and Wound VOX Wound Contact Layers at 10cmx8cm (DK-01-07) and 25cmx17cm (DK-01-14). FDA classifies the device as a Negative Pressure Wound Therapy Powered Suction Pump under product code OMP, regulation 878.4780, class 2, in the General and Plastic Surgery advisory committee. [1][4]
The decision code is SESE, described by FDA as Substantially Equivalent, and the clearance type is Traditional with no third-party review. The record notes a summary statement and lists the applicant contact as John Gvodas at 300 Schell Ln., Suite 305, Phoenixville, PA 19460. The submission was received June 30, 2026 and decided November 6, 2026. [1]
Filing timeline and review duration
FDA's 510(k) final-decision listing for decisions rendered since October 1, 2026 carries K262232 with a Substantially Equivalent decision published November 6, 2026, alongside unrelated clearances such as K260044 for Aesculap, Inc. and K263749 for BeamWorks, Inc. The same listing shows the device entry beginning with the Wound VOX name. [2]
A third-party record for K262232 states a review time of 129 days and reports no recalls tied to the clearance in FDA's recall database as of November 19, 2026. That figure is a review-duration observation for this one submission, not a measure of company performance across a portfolio. [5]
Company identity and record counts
Bechtel Medical, Inc. is the applicant named on K262232. A company record page states that, as of November 17, 2026, FDA's public records list Bechtel Medical with two 510(k) clearances, the most recent dated November 6, 2026 for the Wound VOX NPWT System. The linked-record collection assembled for this profile contains one 510(k) record, K262232, with a decision count of one SESE; that count describes the collected filings only and is not a total portfolio, sales or safety measure. [1][7]
Bechtel Medical's own announcement, issued from Phoenixville, Pennsylvania on November 10, 2026, describes the company as designing, engineering and manufacturing wound care devices and dressings in the advanced wound care sector, and states that Wound VOX received 510(k) clearance from FDA. The announcement characterizes Wound VOX as the first 510(k)-cleared combined negative pressure and topical oxygen system; that characterization is the manufacturer's and is not independently confirmed in the FDA record reviewed here. [3]
Product positioning as published
The Wound VOX website, attributed to Bechtel Medical, presents VOX as combining negative pressure wound therapy with topical oxygen therapy and links clinical evidence brochures, including a meta-analysis brochure and a consensus brochure. The site also references a 2022 publication on diabetic foot ulcers treated with cyclical pressurized topical wound oxygen therapy in Advances in Wound Care. Those materials are the manufacturer's published documentation; no outcome figures or treatment guidance from them are restated here. [9]
No parent company, brand ownership, customer list, certification or commercial availability is verified in the records reviewed. The FDA filing address in Phoenixville, Pennsylvania should not be read as a confirmed corporate headquarters, and the number of clearances cited on third-party pages differs from the single linked record in this collection. [1][5][7]


